Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus Capecitabine vs Gemcitabine plus Carboplatin in TNBC
NCT02207335Phase 3Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2013
- Primary completion
- Nov 2016
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in triple-negative breast cancer (TNBC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
capecitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02207335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207335.